GLP-1s may not raise short-term pancreatic cancer risk for adults with type 2 diabetes

Adults with type 2 diabetes who use GLP-1 receptor agonists do not have an increased short-term risk for pancreatic cancer, according to findings published in JAMA Network Open.
“Our findings provide additional reassurance to physicians prescribing GLP-1 receptor agonists to patients,” Rachel Dankner, MD, MPH, senior researcher in the Gertner Institute for Epidemiology and Health Policy Research at Sheba Medical Center In Israel, told Healio. “We were able to show that the lack of an association between GLP-1 receptor agonists and pancreatic cancer risk over 7 years is

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart